Conditional survival after a diagnosis of malignant brain tumour in Canada: 2000-2008
Authors: Y. Yuan, J. Ross, Q. Shi, and F. G. Davis
Background “Conditional survival probability” is defined as the probability that a patient will survive an additional time, given that the patient has already survived a defined period of time after diagnosis. Such estimates might be more relevant for clinicians and patients during post-diagnosis care, because survival probability projections are based on the patient’s survival to date. Here, we provides the first population-based estimates of conditional survival probabilities by histology for brain cancer in Canada. Methods Canadian Cancer Registry data were accessed for patients diagnosed with primary brain cancers during 2000-2008. Kaplan-Meier survival probabilities were estimated by histology. Conditional survival probabilities at 6 months (short-term, denoted scs) and 2 years (long-term, denoted lcs) were derived from the Kaplan-Meier survival estimates for a range of time periods. Results Among the 20,875 patients who met the study criteria, scs increased by a margin of 16-18 percentage points from 6-month survivors to 2-year survivors for the three most aggressive brain cancers. The lcs for 2-year survivors was 66% or greater for all tumour groups except glioblastoma. The lcs for 4-year survivors was 62% or greater for all histologies. For glioblastoma and diffuse astrocytoma, the lcs increased each year after diagnosis. For all other histologies, the lcs first increased and then plateaued from 2 years after diagnosis. The lcs and scs both worsened with increasing older age at diagnosis. Summary We report histologically specific conditional survival probabilities that can have value for clinicians practicing in Canada as they plan the course of follow-up for individual patients with brain cancer.
Please note that abstracts only appear in the language of the publication and might not have a translation.
A. C. Coronado, C. Finley, K. Badovinac, J. Han, J. Niu, and R. Rahal (2018).
Discrepancies between Canadian cancer research funding and site-specific cancer burden
Current Oncology , 338-341
Emily V. Walker, J. Ross, Y. Yuan, T. R. Smith, and F. G. Davis (2019).
Brain cancer survival in Canada 1996-2008: Effects of sociodemographic characteristics
Current Oncology , 292-299
Laetitia Amar, Michelle Le, Feras M. Ghazawi, Elham Rahme, Amanda Segal, Elena Netchiporouk, Gizelle Popradi, Linda Moreau, Osama Roshdy, Denis Sasseville, and Ivan Litvinov (2019).
Prevalence of human T cell lymphotropic virus 1 infection in Canada
Current Oncology , e3-e5
A. Blair, L. Gauvin, S. Ouédraogo, and G. Datta. (2019).
Area-level income and colorectal cancer screening among urban-dwelling Canadians: Evidence to guide future surveillance
Current Oncology , 128-137
Michelle Le, Feras M. Ghazawi, Akram Alakel, Elena Netchiporouk, Elham Rahme, Andrei Zubarev, Mathieu Powell, Linda Moreau, Osama Roshdy, Steven J. Glassman, Denis Sasseville, Gizelle Popradi, and Ivan V. Litvinov (2019).
Incidence and mortality trends and geographic patterns of follicular lymphoma in Canada
Current Oncology , e473-e481
Simon F. Roy, Feras M. Ghazawi, Michelle Le, François Lagacé, Catherine F. Roy, Elham Rahme, Evgeny Savin, Andrei Zubarev, Denis Sasseville, Gizelle Popradi, and Ivan V. Litvinov (2020).
Epidemiology of adult and pediatric Burkitt Lymphoma in Canada: Sequelae of the HIV epidemic
Current Oncology , 83-89
J. Tung, C. E. Politis, J. Chadder, J. Han, J. Niu, S. Fung, R. Rahal, and C. C. Earle (2018).
The north-south and east-west gradient in colorectal cancer risk: A look at the distribution of modifiable risk factors and incidence across Canada
Current Oncology , 231-235